Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
DOP031: Efficacy of infliximab biosimilar CT-P13 therapy on mucosal healing in ulcerative colitis – data from two Central European countries
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 4 - IFX & IFX biosimilars (Keywords: anti-TNF, IBD)
Authors: Renáta Bor
DOP031: Phase I study of intraperitoneal administration of autologous tolerogenic dendritic cells for refractory Crohns disease.
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 4 – Controlled & uncontrolled trials in IBD
Authors: Aranzazu Jauregui Amezaga
DOP032: 28Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 4 - IFX & IFX biosimilars (Keywords: anti-TNF, biologic treatment, calprotectin, CRP, IBD, CD, UC, infliximab, trough levels, biosimilars)
Authors: Martin Kolar
DOP032: Fistula treatment with adipose derived mesenchymal stem cells - prospective study on experimental model of perianal Crohns disease
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 4 – Controlled & uncontrolled trials in IBD (Keywords: anti-TNF, enterocutaneous fistula, fistula, CD)
Authors: Ondrej Ryska
DOP033: Efficacy and safety of anti-TNF therapy for inflammatory bowel disease (IBD) in liver transplant recipients for primary sclerosing cholangitis (PSC): a multicenter experience.
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 4 – Controlled & uncontrolled trials in IBD (Keywords: adalimumab, anti-TNF, colorectal cancer surveillance, IBD, CD, UC, immunosuppressive agents, infliximab, tacrolimus, liver transplantation)
Authors: Roman Combes
DOP033: Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohort
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 4 - IFX & IFX biosimilars (Keywords: anti-TNF, biologic treatment, IBD, CD, UC, infliximab)
Authors: Barbara Lovasz
DOP034: Comparative effectiveness of infliximab and adalimumab in Crohn’s disease: results from a real-life population-based cohort
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 4 - IFX & IFX biosimilars (Keywords: adalimumab, anti-TNF, disease outcome, CD, infliximab)
Authors: Steven Jeuring
DOP034: Efficacy of adalimumab in patients with Crohns disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort study (CREOLE)
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 4 – Controlled & uncontrolled trials in IBD (Keywords: adalimumab, complications, CD, MRI)
Authors: Yoram Bouhnik
DOP035: Anti-TNF withdrawal in IBD: Relapse and recapture rates and predictive factors from 160 patients in a pan-UK study
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 4 – Controlled & uncontrolled trials in IBD (Keywords: adalimumab, anti-TNF, biologic treatment, calprotectin, disease outcome, endoscopic asessment, IBD, CD, UC, infliximab, monitoring, drug withdrawal)
Authors: Nicholas A Kennedy
DOP035: Longterm outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα –blocking agents
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 4 - IFX & IFX biosimilars (Keywords: biologic treatment, disease outcome, IBD)
Authors: Pauliina Molander
DOP036: Infliximab discontinuation is associated with a higher risk for relapse in patients with ulcerative colitis in remission: a multinational collaborative retrospective study
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 4 - IFX & IFX biosimilars (Keywords: disease outcome, UC, linfliximab)
Authors: Gionata Fiorino
DOP036: PYRAMID registry: an observational study of adalimumab in Crohns disease: results at year 6
Source: Presentation - ECCO 2015 Barcelona Congress -Digital Oral Presentation Session 4 – Controlled & uncontrolled trials in IBD
Authors: Geert D'Haens
DOP037: Excess steroid use in IBD: too much, how much and why? Results from a UK nationwide audit
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 5 - Improving the care and outcome of IBD patients (Keywords: ECCO, IBD, CD, UC)
Authors: Christian Selinger
DOP037: Initial Adequate Trough Concentrations during Induction Therapy Correlate with Sustained TNF Suppression and Predict Remission with Adalimumab in Anti-TNF Naive Crohns Disease Patients
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 5 – Drug levels & biomarkers (Keywords: adalimumab, anti-TNF, biologic treatment, clinical trials, CRP, IBD, CD, monitoring, pharmacokinetics, trough levels, immunogenicity)
Authors: Niels Vande Casteele
DOP038: Analytical and clinical validation of a rapid point-of-care assay for infliximab quantification in patients with ulcerative colitis
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 5 - Improving the care and outcome of IBD patients (Keywords: anti-TNF, UC, infliximab, monitoring, trough levels)
Authors: Thomas Van Stappen
DOP038: Faecal calprotectin measurement and infliximab trough levels predict therapeutic evolution CD patients in clinical remission
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 5 – Drug levels & biomarkers (Keywords: CD, infliximab, monitoring, pharmacokinetics)
Authors: Xavier Roblin
DOP039: Early therapeutic drug monitoring for prediction of short-term mucosal healing in patients with ulcerative colitis treated with infliximab
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 5 – Drug levels & biomarkers
Authors: Konstantinos Papamichail
DOP039: Point-of-care monitoring of infliximab trough levels in capillary fingerstick blood of patients with inflammatory bowel disease (IBD)
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 5 - Improving the care and outcome of IBD patients (Keywords: biologic treatment, infliximab, monitoring, point of care test, therapeutic drug monitoring)
Authors: Jeroen Maljaars
DOP040: Effects of education and information on vaccination behavior in IBD patients
Source: Presentation - ECCO 2016 Amsterdam Congress - Digital Oral Presentation Session 5 - Improving the care and outcome of IBD patients (Keywords:IBD, UC, CD, immunization, vaccinations, education, quality care)
Authors: Sofie Coenen
DOP040: Relationship between vedolizumab pharmacokinetics and endoscopic outcomes in patients with Ulcerative Colitis
Source: Presentation - ECCO 2015 Barcelona Congress - Digital Oral Presentation Session 5 – Drug levels & biomarkers (Keywords: IBD, CD, UC, tough levels, vedolizumab)
Authors: Maria Rosario